Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Joint Venture

  • Financing Rounds
  • 1

Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) General Information

Description

Developer of drugs for the treatment of viral hemorrhagic fever viruses. The joint venture is focused on monoclonal antibody (mAb) drugs for the treatment of viral hemorrhagic fever viruses e.g. Ebola or Marburg viruses.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Corporate Office
  • United States
Primary Industry
Buildings and Property
Corporate Office
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical)‘s full profile, request access.

Request a free trial

Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical)‘s full profile, request access.

Request a free trial

Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) FAQs

  • When was Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) founded?

    Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) was founded in 2013.

  • Where is Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) headquartered?

    Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) is headquartered in .

  • What industry is Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) in?

    Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical)’s primary industry is Buildings and Property.

  • Is Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) a private or public company?

    Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) is a Private company.

  • What is Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical)’s current revenue?

    The current revenue for Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) is .

  • Who are Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical)’s investors?

    Defyrus and Mapp Biopharmaceutical have invested in Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process